The Global Health Body Sounds Alert Over Acute Shortage of Obesity Injections

Less than a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy have access to them, states the WHO as it publishes its initial advice on the drugs.

With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication.

Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"The latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are significant hurdles to universal availability to the injections that can aid individuals in losing considerable weight, explains the organization.

GLP-1 Therapy Shortage

Even in the current most favorable outlook, the supply of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The advice encourages countries and companies to increase access, by strategies such as licensing agreements.

A patent on semaglutide – the main ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.

The Way Obesity Jabs Operate

GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals eat less.

People commonly see weight reduction in the initial weeks of commencing the once-weekly jabs.

Evidence indicates patients may regain a significant portion after a year of halting the drug, as their typical appetite resume.

To be above a healthy weight raises your chance for contracting diseases, such as type 2 diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.